Here, we sought to investigate whether PD-L1 expression affects the efficacy of EGFR-TKIs and the clinical outcome in untreated metastatic EGFR-mutated lung adenocarcinoma patients. This evidence concerns the gene CD274 and lung adenocarcinoma.